Page last updated: 2024-11-13
cd 3254
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CD 3254: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44566110 |
| CHEMBL ID | 491294 |
| SCHEMBL ID | 13343636 |
| MeSH ID | M0516721 |
Synonyms (18)
| Synonym |
|---|
| cd 3254 |
| (e)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6, 7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid |
| cd-3254 |
| cd3254 |
| gtpl2810 |
| CHEMBL491294 |
| 196961-43-0 |
| (e)-3-[4-hydroxy-3-(1,1,4,4,7-pentamethyltetralin-6-yl)phenyl]prop-2-enoic acid |
| SCHEMBL13343636 |
| 3-[4-hydroxy-3-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)phenyl]-2-propenoic acid |
| AKOS024457538 |
| J-012733 |
| Q27075803 |
| (e)-3-(4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl)acrylic acid |
| (e)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid |
| WHA96143 |
| 3-[4-hydroxy-3-(5,6,7,8-tetrahtdro-3,5,5,8,8-pentamethyl-2-naphthalenyl)phenyl]-2-propenoic acid |
| AKOS040741522 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1069743 | Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of biotinylated SRC-1-676-700 coactivator recruitment after 4 hrs by TR-FRET assay (Rvb = 148 +/- 7%) | 2014 | Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4 | Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. |
| AID1069748 | Antagonist activity at Gal4-fused RARalpha (unknown origin) transfected in HEK293 cells assessed as ATRA-induced transcriptional activity at 4 uM by luciferase/beta-galactosidase reporter gene assay relative to ATRA-treated control | 2014 | Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4 | Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. |
| AID1069750 | Agonist activity at Gal4-fused RARalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 6 hrs by luciferase/beta-galactosidase reporter gene assay relative to control | 2014 | Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4 | Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. |
| AID1069749 | Agonist activity at Gal4-fused RXRalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 24 hrs by luciferase/beta-galactosidase reporter gene assay relative to control | 2014 | Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4 | Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. |
| AID1525213 | Binding affinity to recombinant human RXRalpha LBD (592 to 1386 residues) expressed in Escherichia coli BL21 (DE3) by fluorescence quenching assay | 2019 | Journal of natural products, 05-24, Volume: 82, Issue:5 | Cytotoxic Components from Hypericum elodeoides Targeting RXRα and Inducing HeLa Cell Apoptosis through Caspase-8 Activation and PARP Cleavage. |
| AID1069744 | Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of fluorescein labeled D22 coactivator recruitment after 4 hrs by TR-FRET assay relative to control | 2014 | Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4 | Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids. |
| AID350577 | Activity at RARalpha/RXRalpha ligand binding domain assessed as stabilization of RXR helix H12 by fluorescence anisotropy in presence of 1 uM coactivator peptide TIF-NR2 | 2009 | Journal of medicinal chemistry, May-28, Volume: 52, Issue:10 | Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||